Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35

Benzinga Newsdesk www.benzinga.com Negative 76.3%

Neg 76.3% Neu 0% Pos 0%

Barclays analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and lowers the price target from $39 to $35.